> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Atropine Sulfate Not Withdraw Over Safety/Efficacy
- URL: https://www.fdaweb.com/atropine-sulfate-not-withdraw-over-safety-efficacy/
- Published: 2019-09-25T12:00:00.000Z
- Updated: 2026-09-15T01:52:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145088

*Federal Register* notice: FDA has determined that Hospira’s atropine sulfate ansyr plastic syringe (atropine sulfate solution) intravenous, intramuscular, subcutaneous, and endotracheal, 0.5mg/5 mL, was not withdrawn due to safety or effectiveness reasons. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-09-24/pdf/2019-20662.pdf?ref=fdaweb.com).